Nasus Pharma, Ltd. (NSRX) Short-Term Debt to Equity

The asset value tracked on this chart demonstrates a debt-to-equity ratio of 0.00. Nasus Pharma Ltd (NSRX) dominates a niche segment of nasal systems, leveraging patent protection to maintain pricing power. The company's environmental development vector is reflected in the reduction of toxic waste and an ethical approach to compliance. High growth potential is driven by a unique drug delivery method that reduces production costs.

Liquidity is critical for Nasus Pharma Ltd (NSRX), which is scaling its intranasal drug delivery systems, to conduct clinical trials. By analyzing the current trend of short-term liabilities to equity, an investor assesses the proportion of obligations maturing within one year relative to shareholders' equity, which determines the startup's dependence on rapid refinancing. The stability of this ratio confirms the financial resilience of Nasus Pharma Ltd (NSRX) during its preparation for licensing agreements.